Hanx Biopharmaceuticals publishes 2025 annual report

PUBT·04/27/2026 09:45:09

Listen to the news

Hanx Biopharmaceuticals released annual report for year ended Dec. 31, 2025, highlighting transition into capital markets following Hong Kong listing under stock code 3378.
R&D focus stayed on immuno-oncology, ADCs, autoimmune diseases, with pipeline positioned as three clinical-stage candidates plus one IND-stage asset.
Flagship HX009 advanced with positive interim efficacy signals in EBV-positive lymphoma, acral or mucosal melanoma.
CTLA-4/SIRPα fusion protein HX044 expanded global development with parallel enrollment in China, Australia, targeting ICI-resistant solid tumors.
First ADC candidate HX111, targeting OX40, secured NMPA IND clearance, with first-in-human trial planned in early 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanx Biopharmaceuticals (Wuhan) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260427-12125131), on April 27, 2026, and is solely responsible for the information contained therein.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number :+852 3852 8500

Monday 7:00 AM - Saturday 9:00 AM (HKT)

Service Email :service@webull.hk

Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)

Business Cooperation :marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English